CAR-T Indication-Based Pricing May Be Evaluated In Medicare Demo
Novartis exec discusses details around its agreements with CMS for outcomes based payments and indication-based pricing for Kymriah.
You may also be interested in...
'It's not for every medication,' CMS administrator says, but agency continues to explore how to apply value-based pricing.
Novartis, Gilead/Kite and Celgene protest the US Centers for Medicare and Medicaid Services’ decision to launch a Medicare coverage analysis for CAR-T drugs because it might lead to coverage restrictions.
Industry should be encouraged by Blueprint's interest in examining impact of Medicaid rebates, the annual excise tax, and the 340B program. Document also confirms Administration’s interest in value-based contracting.